Orchestra BioMed (NASDAQ:OBIO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...

BTIG Research initiated coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.

Fintel reports that on March 20, 2025, BTIG initiated coverage of Orchestra BioMed Holdings (NasdaqGM:OBIO) with a Buy recommendation. Analyst Price Forecast Suggests 247.03% Upside As of March 19, ...

BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed (OBIO) with a Buy rating and $12 price target Orchestra is a medical ...

Highlights,Orchestra BioMed (NASDAQ:OBIO) operates within the biomedical innovation sector.,Stock performance has experienced notable fluctuations throughout the past year.,Institutional investment ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

This page features the latest news about the Orchestra Biomed Holdings stock. OBIO stock touches 52-week low at $3.75 amid market challenges In a challenging market environment, Health Sciences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Featured here, the Cash Flow Statement for Orchestra Biomed Holdings Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities ...